Related references
Note: Only part of the references are listed.Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
Stephen Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Small-cell lung cancer
Charles M. Rudin et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer
James W. Welsh et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
Hyun Cheol Chung et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
The future of cancer immunotherapy: microenvironment-targeting combinations
Yonina R. Murciano-Goroff et al.
CELL RESEARCH (2020)
Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.
Ticiana Leal et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Small Cell Lung Cancer: Advances in Diagnosis and Management
Ayushi F. Chauhan et al.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
Targeted Therapies and Biomarkers in Small Cell Lung Cancer
Hirokazu Taniguchi et al.
FRONTIERS IN ONCOLOGY (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Immune Cell Infiltration May Be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer
Prasuna Muppa et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study
Claus-Christoph Steffens et al.
LUNG CANCER (2019)
Current Diagnosis and Management of Small-Cell Lung Cancer
Shuhang Wang et al.
MAYO CLINIC PROCEEDINGS (2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET (2019)
A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer
Yu-Jung Kim et al.
LUNG CANCER (2019)
Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer
Neil H. Segal et al.
CLINICAL CANCER RESEARCH (2018)
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)
Shirish M. Gadgeel et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
PD-L1 Expression in Small Cell Lung Cancer
Yuto Yasuda et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
Hyun Cheol Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
NCCN Guidelines® Insights Small Cell Lung Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines
Gregory P. Kalemkerian et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Prophylactic Cranial Irradiation (PCI) versus Active MRI Surveillance for Small Cell Lung Cancer: The Case for Equipoise
Chad G. Rusthoven et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel et al.
NATURE (2017)
Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor
Kentaro Inamura et al.
CANCER MEDICINE (2017)
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
Glen J. Weiss et al.
BRITISH JOURNAL OF CANCER (2017)
Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032.
Matthew David Hellmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy
Alfonso R. Sanchez-Paulete et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2016)
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC
Edurne Arriola et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer
Andrew G. Nicholson et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations
Andreas H. Scheel et al.
ONCOIMMUNOLOGY (2016)
Comprehensive genomic profiles of small cell lung cancer
Julie George et al.
NATURE (2015)
DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2
J. T. Poirier et al.
ONCOGENE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
PD-L1 and Survival in Solid Tumors: A Meta-Analysis
Pin Wu et al.
PLOS ONE (2015)
SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome
Carmen S. Tellez et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer
J. S. Ross et al.
JOURNAL OF CLINICAL PATHOLOGY (2014)
EZH2 Promotes E2F-Driven SCLC Tumorigenesis through Modulation of Apoptosis and Cell-Cycle Regulation
Roland Hubaux et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer
Charles M. Rudin et al.
NATURE GENETICS (2012)
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database
Ramaswamy Govindan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Share Paper
